Brimonidine is a medication used to treat open-angle glaucoma, ocular hypertension, and rosacea. In rosacea it improves the redness. It is used as eye drops or applied to the skin.Common side effects when used in the eyes include itchiness, redness, and a dry mouth. Common side effects when used on the skin include redness, burning, and headaches. More significant side effects may include allergic reactions and low blood pressure. Use in pregnancy appears to be safe. When applied to the eye it works by decreasing the amount of aqueous humor made while increasing the amount that drains from the eye. When applied to the skin it works by causing blood vessels to contract.Brimonidine was patented in 1972 and came into medical use in 1996. It is available as a generic medication. In 2019, it was the 217th most commonly prescribed medication in the United States, with more than 2 million prescriptions. Medical uses
Brimonidine is indicated for the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. It is also the active ingredient of brimonidine/timolol along with timolol maleate. A 2017 Cochrane review found insufficient evidence to determine if brimonidine slows optic nerve damage.In 2013, the FDA approved topical application of brimonidine 0.33% gel for persistent facial redness of rosacea. Mechanism of action
Brimonidine is an α2 adrenergic agonist.α2 agonists, through the activation of a G protein-coupled receptor, inhibit the activity of adenylate cyclase. This reduces cAMP and hence aqueous humour production by the ciliary body.
Other radium-223-based compounds
Although radium does not easily form stable molecular complexes, data has been presented on methods to increase and customize its specificity for particular cancers by linking it to monoclonal antibodies, by enclosing the 223Ra in liposomes bearing the antibodies on their surface. See also
Actinium-225
Actinium series
Bismuth-213
Isotopes of radium
Radium chloride

References
External links
"Radium-223". Drug Information Portal. U.S. National Library of Medicine. "FDA approves new drug for advanced prostate cancer" (Press release). US FDA. Archived from the original on 4 June 2013. Retrieved 16 December 2019.